Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood
Z Liu, J Martin, L Orme, B Seddon, J Desai, W Nicholls, D Thomson, D Porter, G McCowage, C Underhill, N Cranswick, M Michael, M Zacharin, A Herschtal, J Sivasuthan, DM Thomas
CANCER CHEMOTHERAPY AND PHARMACOLOGY | SPRINGER | Published : 2018
PURPOSE: For many cancers, adolescents and young adults (AYA) have worse outcomes than for children and adults. Many factors may contribute to the AYA survival gap, including differences in biology, therapeutic intent, and adherence to therapy. It has been observed that male AYAs have poorer outcomes than females. The purpose of this work was to test the proposition that gender-related pharmacologic factors may account for a component of the AYA survival gap. PATIENTS AND METHODS: A prospective, multi-institutional pharmacologic study of 79 patients in total with chemosensitive cancers (Ewing sarcoma, osteosarcoma and Hodgkin lymphoma) was conducted, with conventional doxorubicin treatment. ..View full abstract
Awarded by Victorian Cancer Agency
Funding was provided by Victorian Cancer Agency (Grant no. CTPS_08_18).